TNBC, which is the most aggressive subtype of breast cancer without an expression of the progesterone receptor, estrogen receptor, and human epidermal growth factor receptor 2, accounts for 10–20% of all breast cancers (Venkitaraman, 2010; Hudis and Gianni, 2011). This evidence concerns the gene ERBB2 and breast carcinoma.